Search
Verrica Pharmaceuticals Inc
VRCAAdd to Watchlist
4.450USD
-0.200-4.30%
Close 09-18 16:00（ET）
77.48MMarket Cap
LossP/E TTM
Verrica Pharmaceuticals Inc (VRCA) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Verrica Pharmaceuticals Inc in the past month.
Buy
1 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
13.833USD+202.04%
VRCA Analyst Recommendation Trends
In the current month, VRCA has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VRCA average Analyst price target in the last month is 13.833.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
1
5
5
4
4
3
3
3
3
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
6
6
5
5
5
5
VRCA Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
9
21
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Regeneron Pharmaceuticals Inc
REGN
6
15
11
0
0
32
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Pfizer Inc
PFE
5
6
19
1
1
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Financial Forecasting
Based on analysts' estimates, VRCA EPS is projected to reach -0.471 in FY2026Q3, following reported EPS of -0.617 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.79
-0.45
-0.42
-0.47
-0.44
Actual
-0.57
-0.45
-0.62
--
--
Surprise
+28.12%
-0.14%
-46.30%
--
--
FAQs
What is Verrica Pharmaceuticals Inc's expected revenue for the next quarter?
Verrica Pharmaceuticals Inc's expected revenue is 6.74M.
What is Verrica Pharmaceuticals Inc's price target?
Analysts forecast that Verrica Pharmaceuticals Inc's price target is USD 13.83, with the highest forecast at USD 20.00 and the lowest forecast at USD 9.00.
How have Verrica Pharmaceuticals IncVRCA's recent earnings per share performed?
The market expectation was USD -0.62, while Verrica Pharmaceuticals IncVRCA's earnings per share (EPS) for the previous quarter was USD -0.45. EPS for the next quarter is expected at USD -0.47.
What is the analyst rating for Verrica Pharmaceuticals Inc?
Based on the ratings of Verrica Pharmaceuticals Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.